113 related articles for article (PubMed ID: 32337038)
21. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study.
Beisland C; Johannesen TB; Klepp O; Axcrona U; Torgersen KM; Kowalski J; Solli O; Sandin R; Oldenburg J
Onco Targets Ther; 2017; 10():371-385. PubMed ID: 28144152
[TBL] [Abstract][Full Text] [Related]
22. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
[TBL] [Abstract][Full Text] [Related]
23. A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
Kim SH; Kim S; Joo J; Seo HK; Joung JY; Lee KH; Chung J
BMC Cancer; 2016 Aug; 16():577. PubMed ID: 27484254
[TBL] [Abstract][Full Text] [Related]
24. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
[TBL] [Abstract][Full Text] [Related]
25. Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations.
Lindskog M; Wahlgren T; Sandin R; Kowalski J; Jakobsson M; Lundstam S; Ljungberg B; Harmenberg U
Urol Oncol; 2017 Sep; 35(9):541.e15-541.e22. PubMed ID: 28623071
[TBL] [Abstract][Full Text] [Related]
26. Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution.
Uccello M; Alam T; Abbas H; Nair A; Paskins J; Faust G
Clin Genitourin Cancer; 2019 Jun; 17(3):e658-e663. PubMed ID: 31000484
[TBL] [Abstract][Full Text] [Related]
27. Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study.
Stroup SP; Raheem OA; Palazzi KL; Liss MA; Mehrazin R; Kopp RP; Patel N; Cohen SA; Park SK; Patterson AL; Kane CJ; Millard F; Derweesh IH
Urology; 2013 Apr; 81(4):805-11. PubMed ID: 23414694
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.
Kalra S; Verma J; Atkinson BJ; Matin SF; Wood CG; Karam JA; Lin SH; Satcher RL; Tamboli P; Sircar K; Rao P; Corn PG; Tannir NM; Jonasch E
Clin Genitourin Cancer; 2017 Jun; 15(3):363-370. PubMed ID: 28216278
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients.
Takamatsu K; Mizuno R; Tanaka N; Takeda T; Morita S; Matsumoto K; Kosaka T; Shinojima T; Kikuchi E; Asanuma H; Oyama M; Mikami S; Oya M
Int J Clin Oncol; 2019 Sep; 24(9):1069-1074. PubMed ID: 31065836
[TBL] [Abstract][Full Text] [Related]
30. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2.
Soerensen AV; Donskov F; Hermann GG; Jensen NV; Petersen A; Spliid H; Sandin R; Fode K; Geertsen PF
Eur J Cancer; 2014 Feb; 50(3):553-62. PubMed ID: 24215846
[TBL] [Abstract][Full Text] [Related]
31. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.
Shirotake S; Yasumizu Y; Ito K; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Tanaka N; Mizuno R; Oya M
Clin Genitourin Cancer; 2016 Dec; 14(6):e575-e583. PubMed ID: 27102405
[TBL] [Abstract][Full Text] [Related]
32. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry.
Tsimafeyeu I; Zolotareva T; Varlamov S; Zukov R; Petkau V; Mazhbich M; Statsenko G; Safina S; Zaitsev I; Sakaeva D; Popov A; Borisov P; Vladimirova L
Clin Genitourin Cancer; 2017 Dec; 15(6):e1069-e1072. PubMed ID: 28882737
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
Vickers MM; Al-Harbi H; Choueiri TK; Kollmannsberger C; North S; MacKenzie M; Knox JJ; Rini BI; Heng DY
Clin Genitourin Cancer; 2013 Sep; 11(3):311-5. PubMed ID: 23684422
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC).
Yip SM; Ruiz Morales JM; Donskov F; Fraccon A; Basso U; Rini BI; Lee JL; Bjarnason GA; Sim HW; Beuselinck B; Kanesvaran R; Brugarolas J; Koutsoukos K; Fu SYF; Yuasa T; Davis I; Alva A; Kollmannsberger C; Choueiri TK; Heng DYC
Kidney Cancer; 2017 Jul; 1(1):41-47. PubMed ID: 30334003
[No Abstract] [Full Text] [Related]
36. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
De Lichtenberg TH; Hermann GG; Rørth M; Højer Larsen MJ; Mansourvar Z; Holm ML; Scheike T
Scand J Urol; 2014 Aug; 48(4):379-86. PubMed ID: 24521185
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
[TBL] [Abstract][Full Text] [Related]
38. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
39. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
[TBL] [Abstract][Full Text] [Related]
40. Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma.
Furubayashi N; Negishi T; Yamashita T; Kusano S; Taguchi K; Shimokawa M; Nakamura M
Mol Clin Oncol; 2017 Sep; 7(3):454-460. PubMed ID: 28781819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
